 |
Breakfast and Registration: 7:30 AM - 8:00 PM PT Symposium: 8:00 AM - 9:30 AM PT Wynn Las Vegas Latour 2, Casino Level 3131 Las Vegas Blvd S. Las Vegas, Nevada Co-Chairs: Joanna Hudson, PharmD, BCPS Robert Page, PharmD, MSPH, BCPS, BCGP Faculty: Stephen Greene, MD; Csaba Kovesdy, MD Registration for this program is now closed. |
|
Program Overview:
Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy decreases the risk of major cardiovascular events in patients with heart failure (HF) and chronic kidney disease (CKD) and is recommended in HF and CKD guidelines. In addition, guidelines support the titration of RAASi therapy to achieve target doses to optimize treatment benefits. However, RAASi therapy also increases the risk of hyperkalemia. Hyperkalemia, an electrolyte disorder characterized by elevated levels of serum potassium, is a barrier to optimization of RAASi therapy in patients with HF. Unfortunately, downtitration or discontinuation of RAASi treatment is a common strategy to manage hyperkalemia in routine clinical practice; these actions place patients at increased risk of major adverse clinical events. Novel potassium binders effectively and safely lower serum potassium, potentially enabling patients with HF and CKD to remain on optimal RAASi therapy. In this educational initiative, to take place at the 2025 AXS Specialty Pharmacy meeting, a multidisciplinary faculty—consisting of two hyperkalemia experts in heart failure (one cardiologist, Dr. Stephen Greene and one pharmacist, Dr. Robert Page) and two hyperkalemia experts in chronic kidney disease (one nephrologist, Dr. Csaba Kovesdy and one pharmacist, Dr. Joanna Hudson) will explain the cardiovascular risks associated with discontinuing/reducing the dose of RAASi therapy due to hyperkalemia and the clinical evidence with novel potassium binders for reducing serum potassium and facilitating maintenance of RAASi therapy. Roles of specialty pharmacists in the management of patients with hyperkalemia will be identified, and clinical practice pearls will be described. A case presentation and faculty discussion of a patient with HF, CKD and hyperkalemia at high cardiorenal risk will provide attendees with best practices and key take-home messages. |
|
|
Educational Objectives: At the conclusion of this activity participants should be able to: Accreditation Statement: Continuing Pharmacy Education Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008162-9999-25-091-L01-P) Type of Activity: Knowledge Educational Grant: Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals. Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity. Americans with Disabilities Act | |
In support of improving patient care, this activity
has been planned and implemented by the
Postgraduate Institute for Medicine and Voxmedia
LLC. Postgraduate Institute for Medicine is jointly
accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American
Nurses Credentialing Center (ANCC), to provide continuing education for
the healthcare team.